Dr. Jason Alcorn covers steps 4 and 5 of the GUIDE Communication Framework, explaining how to direct the patient and carer to additional support and the importance of empowering the patient.

Watch the video and download the slides


The GUIDE Communication Framework: Strengthening shared decision-making between nmCRPC patients and the healthcare team

This is the last in a series of three newsletters explaining the GUIDE Communication Framework, a simple 5-step approach to optimise the role of the nurse in strengthening shared decision-making between nmCRPC patients and their healthcare team.

GUIDE’s five letters each represent a crucial step in your conversations with patients with prostate cancer.

  • Gain insight into goals of treatment and care
  • Understand gaps in the patient's knowledge
  • Inform and educate
  • Direct to additional support
  • Empower the patient

Dr. Jason Alcorn explains how to Direct the patient and the carer to additional support and the importance of Empowering the patient, making them feel they can actively participate in the shared decision-making and treatment process, and why these steps are an important part of a successful treatment journey.

In the first newsletter, Veerle Lamotte covered steps 1 and 2 of the GUIDE framework and explained why it’s important to Gain insight into the goals of treatment and care as a first step in supporting your patients along the agreed treatment journey and how to Understand the gaps in the patient’s knowledge, allowing you to prioritise where you focus when it comes to informing and educating the patient.

In the second newsletter, Joanie Pfahl and Jennifer Sutton covered step 3 of the GUIDE Communication Framework and explain the importance of Informing and educating the patient, and why it is essential for nurses to have up-to-date knowledge about the disease and common symptoms, key studies relating to nmCRPC, treatment aims and options, potential side effects and proactive management as addressing patients’ knowledge gaps in the right way is critical in managing their treatment successfully.

Hello, I am Dr Jason Alcorn and I'm from The Mid Yorkshire Hospitals NHS Trust in the United Kingdom.

I'm going to be talking about the strengthening shared decision-making between non-metastatic castrate-resistant prostate cancer patients and the healthcare team.

Directing the patient to additional support and Empowering the patient

This is using the GUIDE Communication Framework. I will be talking about directing to additional support and empowering the patient. If we consider the first step is directing patients to additional support, we must consider all the local options available in our areas, centres or regions.

We must consider the information provision to patients and ensuring the patient understands the information provided.

Empowering the patient by involving them in the shared decision-making process can increase the likelihood of treatment success.

As Uro-oncology nurses, we play a vital role in this process, we undertake holistic reviews of patients and ensure the patients have the right knowledge.  Factors to consider are: the physical and psycho-social aspects, such as any existing comorbidities, or barriers that the patients may face such as psychological distress of the disease.

Also understanding the treatment options of darolutamide, apalutamide and enzalutamide. These may present with potential drug interactions.  We must understand the safety profile or any polypharmacy that the patient may have and also consider bone health.

We must take into account the quality of life of the patient and also their wishes, these are paramount to involving them in their treatment and decision-making process.

To download the slides go to gunursesconnect.cor2ed.com. Thank you for listening on behalf of GU Nurses CONNECT and remember - download the slides.

Jason Alcorn is the Nurse Consultant for Uro-oncology and Andrology at the Mid Yorkshire Hospitals NHS Trust.  He has worked at the Trust for 20 years. The Mid Yorkshire Hospitals NHS Trust is a specialist cancer centre for urological cancers. Jason started in the nursing profession after a career in the military.  After completing a Bachelor’s degree developing student nurse resources, he then studied for a Master’s degree seeking to understand registered nurse understanding of delegation to healthcare assistants.  This led to him being a fellow of the higher education academy and a registered teacher.  He then studied for a professional doctorate seeking to understand why patients withdraw early from Bacillus Calmette-Guerin treatment for urothelial cancer. Jason has presented at several national and international conferences, as well as running workshops locally and in the Middle East on behalf of EAUN, and he has also published several articles from his research activity.  He is an active board member of the European Association of Urological Nurses (EAUN) and his responsibilities on the board include education, accreditation and endorsement. __________________________

Programme summary
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU NURSES CONNECT

GU NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer, and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

eks
EKS / On-demand webinar
Oncology 
Multiple Myeloma: Is it time to rethink how we sequence treatments?

On-demand materials from an Experts Knowledge Share event

Experts
Prof. Karthik Ramasamy, Dr Joshua Richter, Dr Faisal Basheer, Dr Andrew Charlton
  • download Downloadable
    Resources
  • clock 80 MIN
  • calendar Mar 2026

This programme has been sponsored by Menarini Stemline and is intended for HCPs in the UK only    MAT-GB-SEL-00774
conference-update Conference update

Episode

2

of 2

episode
Oncology Rare diseases Endocrinology 
Actualités du Congrès l’ENETS 2026

Points de vue d’experts sur les dernières données concernant le cancer neuroendocrinien

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Cette vidéo est soutenue par une subvention indépendante à visée éducative d’Ipsen.  Les contenus publiés sur ce site internet sont sous la responsabilité de leurs auteurs. Certaines données scientifiques publiées sur ce site sont susceptibles de ne pas être validées par la commission d’Autorisation de Mise sur le Marché, et ne doivent pas être mises en pratique. Elles doivent être lues et comprises avec le plus grand discernement et sont données dans leur cadre de la diffusion de l’information sur l’état actuel de la recherche auprès de la communauté scientifique internationale  
conference-update Conference update

Episode

1

of 2

episode
Oncology Rare diseases Endocrinology 
Update from ENETS 2026

Experts share their views on latest data in neuroendocrine cancer

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
patient-support Patient Support
Oncology Hemato-oncology Pediatrics 
Personalised treatment in childhood cancer: A journey through NTRK fusion testing

Experts
Linet Menachery
Endorsed by
NTRKers ICAN international cancer advocacy network Biomarker Collaborative
  • clock 4 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
conference-update Conference update
Oncology 
Update from ESGO 2026 – PYNNACLE Phase 2 study: Interim results from the ovarian cancer cohort

Clinical insights and expert discussion

Experts
Prof. Domenica Lorusso, Prof. Jean-Sebastien Frenel
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Mar 2026

This programme has been sponsored by PMV Pharma and is intended for HCPs only.